SecBot SecBot
Biotech Drug Report Generated Oct 24, 2026

Napazimone

PHAR·Pharming Group N.V.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Unknown (early-stage/preclinical or Phase 1)
Time to market
Unknown, FALCON trial enrollment expected to complete H1 2027, topline results ~H1 2028 at earliest, followed by potential regulatory filing
Why 4/10
Napazimone is an early-stage pipeline candidate at Pharming. The next hard catalyst is the FALCON trial enrollment completion expected in H1 2027, with topline results not expected until approximately H1 2028, more than 12 months out. No PDUFA or pivotal readout is scheduled within the next year.
Actionable Insight NEUTRAL

Napazimone is a very early-stage pipeline asset with no near-term binary catalyst. Pharming's near-term value drivers are its approved products RUCONEST and Joenja (leniolisib), plus the upcoming Phase II CVID readout for leniolisib in November 2026 and the Joenja pediatric sNDA PDUFA on January 30, 2027. Napazimone is not investable as a standalone catalyst at this stage.

Price Chart

Loading chart...

Executive Summary

Napazimone is an early-stage pipeline candidate at Pharming Group N.V. (Nasdaq: PHAR), a commercial-stage biotech focused on rare diseases. Very little public information is available about this drug, it is not listed on ClinicalTrials.gov under that name, and no clinical data have been published. The only concrete reference comes from Pharming's October 2026 preliminary Q3 earnings filing, which mentions that the FALCON trial enrollment for napazimone has been delayed to H1 2027, with topline results not expected until roughly H1 2028. Pharming's near-term value is driven by its two approved products: RUCONEST (conestat alfa) for hereditary angioedema and Joenja (leniolisib) for APDS, plus pipeline expansion of leniolisib into broader indications. Napazimone is not a near-term catalyst for the stock.

How It Works

Napazimone is an investigational drug candidate being developed by Pharming Group. Its specific mechanism of action is not publicly detailed in available sources. Pharming's expertise is in protein replacement therapies for rare diseases (RUCONEST for hereditary angioedema) and targeted small molecules (Joenja/leniolisib for APDS).

Trial Status

The FALCON trial for napazimone has experienced enrollment delays, now expected to complete enrollment in H1 2027, pushing topline results to approximately H1 2028. No clinical trial data or results are publicly available in SecBot's ingested databases.

The Two-Sided Case

▲ Bull Case3
Pharming is a commercial-stage company with growing revenue (~US$117.6M in Q3 2026, +21% YoY) from two approved products, providing financial stability to fund pipeline development.
The FALCON trial enrollment completion in H1 2027, while delayed, indicates the program is still active and progressing.
Pharming has strong analyst support (12 Buy/Strong Buy vs 1 Hold, mean price target ~US$34.35 implying ~207% upside from ~US$11.20).
▼ Bear Case5
Napazimone is extremely early-stage with essentially no public clinical data, its mechanism, phase, and target indication are not confirmed in any publicly available source.
The FALCON trial has already experienced enrollment delays (pushed to H1 2027), suggesting potential development challenges.
Pharming's pipeline focus appears to be on leniolisib label expansion (APDS pediatric, CVID, genetic PIDs), making napazimone a lower-priority asset.
CEO departure in September 2026 due to strategic misalignment adds uncertainty around pipeline prioritization.
The stock trades near its 52-week low (~US$9.11) and well below the mean analyst target, reflecting execution concerns.

Upcoming Catalysts

  • FALCON trial enrollment completion for napazimone expected H1 2027
  • Topline Phase II results for leniolisib in CVID expected November 2026
  • PDUFA date for Joenja lower-dose pediatric sNDA: January 30, 2027
  • Full Q3 2026 results and business update: October 27, 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Pharming Group N.V. 6-K PHAR ·Originating report

Sources · 10

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov6 sec.gov7 sec.gov8 sec.gov9 sec.gov10 sec.gov